Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-888X
  • E-ISSN: 2212-3946

Abstract

Background

Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the neoplastic proliferation of plasma cells, which produce monoclonal immunoglobulin that can cause vital organ damage, subsequently leading to significant morbidity and mortality. Autologous hematopoietic stem cell transplant (ASCT) is the standard-of-care management of eligible patients with newly diagnosed MM. Experts recommend collecting enough stem cells upfront to support a possible tandem transplant, salvage ASCT, or a stem cell “boost” to allow for the administration of multiagent cytotoxic chemotherapy in patients with relapsed/refractory disease.

Objective

There is currently a paucity of data on the response rates and outcomes of patients with relapsed MM who undergo cytotoxic chemotherapy followed by a stem cell boost; this study examines the outcomes of patients treated with this approach.

Methods

We conducted a retrospective chart review from two oncologic treatment centers in the United States of adult patients who underwent a first ASCT between 1999 and 2021 and subsequently received cytotoxic chemotherapy followed by stem cell boost further on in their disease course. Survival analysis was carried out using the Kaplan-Meier method, and the log-rank test was used to compare survival curves.

Results

We found that the majority (56.6%) of these patients responded to therapy and that 60.6% of these patients were able to receive at least one subsequent line of therapy post-boost. Furthermore, patients who responded to therapy had significantly longer median overall survival compared to those who did not respond (323 days 93 days, p=0.0045), and age did not affect response to therapy.

Conclusion

This data allow clinicians to appropriately implement and inform patients of the therapeutic uses and clinical outcomes of stem cell boost in patients with multiply relapsed/refractory MM.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cscr/10.2174/011574888X287532240325041249
2024-04-03
2025-12-08

  • From This Site

    /content/journals/cscr/10.2174/011574888X287532240325041249
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. van de DonkN.W.C.J. UsmaniS.Z. YongK. CAR T-cell therapy for multiple myeloma: State of the art and prospects.Lancet Haematol.202186e446e46110.1016/S2352‑3026(21)00057‑034048683
     [Google Scholar]
  2. LandgrenO. KyleR.A. PfeifferR.M. KatzmannJ.A. CaporasoN.E. HayesR.B. DispenzieriA. KumarS. ClarkR.J. BarisD. HooverR. RajkumarS.V. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study.Blood2009113225412541710.1182/blood‑2008‑12‑19424119179464
     [Google Scholar]
  3. RichardsonP.G. JacobusS.J. WellerE.A. HassounH. LonialS. RajeN.S. MedvedovaE. McCarthyP.L. LibbyE.N. VoorheesP.M. OrlowskiR.Z. AndersonL.D.Jr ZonderJ.A. MilnerC.P. GasparettoC. AghaM.E. KhanA.M. HurdD.D. GowinK. KambleR.T. JagannathS. NathwaniN. AlsinaM. CornellR.F. HashmiH. CampagnaroE.L. AndreescuA.C. GentileT. LiedtkeM. GodbyK.N. CohenA.D. OpenshawT.H. PasquiniM.C. GiraltS.A. KaufmanJ.L. YeeA.J. ScottE. TorkaP. FoleyA. FulcinitiM. HebertK. SamurM.K. MasoneK. MaglioM.E. ZeytoonjianA.A. NadeemO. SchlossmanR.L. LaubachJ.P. Paba-PradaC. GhobrialI.M. PerrotA. MoreauP. Avet-LoiseauH. AttalM. AndersonK.C. MunshiN.C. DETERMINATION Investigators Triplet therapy, transplantation, and maintenance until progression in myeloma.N. Engl. J. Med.2022387213214710.1056/NEJMoa220492535660812
     [Google Scholar]
  4. GoldschmidtH. LokhorstH.M. MaiE.K. van der HoltB. BlauI.W. ZweegmanS. WeiselK.C. VellengaE. PfreundschuhM. KerstenM.J. ScheidC. CroockewitS. RaymakersR. HoseD. PotamianouA. JauchA. HillengassJ. Stevens-KroefM. RaabM.S. BroijlA. LindemannH.W. BosG.M.J. BrossartP. van Marwijk KooyM. YpmaP. DuehrsenU. SchaafsmaR.M. BertschU. HielscherT. JarariL. SalwenderH.J. SonneveldP. Bortezomib before and after high-dose therapy in myeloma: Long-term results from the phase III HOVON-65/GMMG-HD4 trial.Leukemia201832238339010.1038/leu.2017.21128761118
     [Google Scholar]
  5. GiraltS. CostaL. SchriberJ. DiPersioJ. MaziarzR. McCartyJ. ShaughnessyP. SnyderE. BensingerW. CopelanE. HosingC. NegrinR. PetersenF.B. RondelliD. SoifferR. LeatherH. PazzaliaA. DevineS. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations.Biol. Blood Marrow Transplant.201420329530810.1016/j.bbmt.2013.10.01324141007
     [Google Scholar]
  6. LiangEC Use of backup stem cells for stem cell boost and second transplant in patients with multiple myeloma undergoing autologous stem cell transplantation.Transplant Cell Ther.20212751610.1016/j.jtct.2021.02.026
     [Google Scholar]
  7. CornellR. HariP. TangS. BiranN. CallanderN. ChariA. ChhabraS. FialaM.A. GahvariZ. GandhiU. GodbyK. GuptaR. JagannathS. JagoskyM. KangY. KansagraA. KauffmanM. KodaliS. KumarS.K. LakshmanA. LiedtkeM. LonialS. MaX. MalekE. MansourJ. McGeheeE.F. NeppalliA. PaulB. RichardsonP. ScottE.C. ShachamS. ShahJ. SiegelD.S. UmyarovaE. UsmaniS.Z. VarnadoW. VijR. CostaL. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.Am. J. Hematol.2021961E5E810.1002/ajh.2601032974944
     [Google Scholar]
  8. GillS.K. UnawaneR. WangS. AhnJ. AlemanA. SiegelD.S. VesoleD.H. ParmarH. PhullP. BiranN. I-OPen: Inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.Blood Cancer J.202212913810.1038/s41408‑022‑00733‑236151090
     [Google Scholar]
  9. LakshmanA. SinghP.P. RajkumarS.V. DispenzieriA. LacyM.Q. GertzM.A. BuadiF.K. DingliD. HwaY.L. FonderA.L. HobbsM. HaymanS.R. ZeldenrustS.R. LustJ.A. RussellS.J. LeungN. KapoorP. GoR.S. LinY. GonsalvesW.I. KourelisT. WarsameR. KyleR.A. KumarS.K. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.Am. J. Hematol.201893217918610.1002/ajh.2495429067723
     [Google Scholar]
  10. HemminkiK. FörstiA. HoulstonR. SudA. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.Int. J. Cancer2021149121980199610.1002/ijc.3376234398972
     [Google Scholar]
  11. Ciltacabtagene autoleucel (Carvykti) for multiple myeloma.Med. Lett. Drugs Ther.2022641663e188e18936384766
     [Google Scholar]
  12. Rodriguez-OteroP. AilawadhiS. ArnulfB. PatelK. CavoM. NookaA.K. ManierS. CallanderN. CostaL.J. VijR. BahlisN.J. MoreauP. SolomonS.R. DelforgeM. BerdejaJ. Truppel-HartmannA. YangZ. Favre-KontulaL. WuF. PiaseckiJ. CookM. GiraltS. Ide-cel or standard regimens in relapsed and refractory multiple myeloma.N. Engl. J. Med.2023388111002101410.1056/NEJMoa221361436762851
     [Google Scholar]
  13. BadrosA. BarlogieB. SiegelE. RobertsJ. LangmaidC. ZangariM. DesikanR. ShaverM.J. FassasA. McConnellS. MuwallaF. BarriY. AnaissieE. MunshiN. TricotG. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.Br. J. Haematol.2001114482282910.1046/j.1365‑2141.2001.03033.x11564069
     [Google Scholar]
  14. AttalM. Lauwers-CancesV. HulinC. LeleuX. CaillotD. EscoffreM. ArnulfB. MacroM. BelhadjK. GarderetL. RousselM. PayenC. MathiotC. FermandJ.P. MeulemanN. RolletS. MaglioM.E. ZeytoonjianA.A. WellerE.A. MunshiN. AndersonK.C. RichardsonP.G. FaconT. Avet-LoiseauH. HarousseauJ.L. MoreauP. IFM 2009 Study Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.N. Engl. J. Med.2017376141311132010.1056/NEJMoa161175028379796
     [Google Scholar]
  15. AttalM. HarousseauJ.L. StoppaA.M. SottoJ.J. FuzibetJ.G. RossiJ.F. CasassusP. MaisonneuveH. FaconT. IfrahN. PayenC. BatailleR. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.N. Engl. J. Med.19963352919710.1056/NEJM1996071133502048649495
     [Google Scholar]
  16. ChhabraS. ThapaB. SzaboA. KoningsS. D’SouzaA. DhakalB. JerkinsJ.H. PasquiniM.C. JohnsonB.D. HariP.N. HamadaniM. Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients.Biol. Blood Marrow Transplant.202026112011201710.1016/j.bbmt.2020.07.01932717431
     [Google Scholar]
  17. CookG. WilliamsC. BrownJ.M. CairnsD.A. CavenaghJ. SnowdenJ.A. AshcroftA.J. FletcherM. ParrishC. YongK. CavetJ. HunterH. BirdJ.M. ChalmersA. O’ConnorS. DraysonM.T. MorrisT.C.M. National Cancer Research Institute Haemato-oncology Clinical Studies Group High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): A randomised, open-label, phase 3 trial.Lancet Oncol.201415887488510.1016/S1470‑2045(14)70245‑124948586
     [Google Scholar]
  18. KennedyV.E. WongC. HuangC.Y. KambhampatiS. WolfJ. MartinT.G. ShahN. WongS.W. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.Blood Adv.20215235344534810.1182/bloodadvances.202100502034644387
     [Google Scholar]
/content/journals/cscr/10.2174/011574888X287532240325041249
Loading
Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost
Curr Stem Cell Res Ther 20, 211 (2025); https://doi.org/10.2174/011574888X287532240325041249
/content/journals/cscr/10.2174/011574888X287532240325041249
/content/journals/cscr/10.2174/011574888X287532240325041249
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): cytotoxic therapy; myeloma; Pretreated; relapsed/refractory; salvage; stem cell boost

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test